Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

被引：1
|
作者：
Joensuu, H.
Eriksson, M.
Hatrmann, J.
Hall, K. Sundby
Schutte, J.
Reichardt, A.
Schlemmer, M.
Wardelmann, E.
Ramadori, G.
Al-Batran, S.
Nilsson, B. E.
Monge, O.
Kallio, R.
Sarlomo-Rikala, M.
Bono, P.
Leinonen, M.
Hohenberger, P.
Alvegard, T.
Reichardt, P.
机构：
[1] Univ Helsinki, Cent Hosp, Helsinki, Finland
[2] Univ Lund Hosp, S-22185 Lund, Sweden
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Oslo Univ Hosp, Oslo, Norway
[5] Marien Hosp Duesseldorf, Dusseldorf, Germany
[6] HELIOS Klinikum Berlin Buch, Sarcoma Ctr Berlin Brandenburg, Berlin, Germany
[7] Univ Munich, Univ Hosp Grosshadern, Munich, Germany
[8] Univ Bonn, Bonn, Germany
[9] Univ Gottingen, D-37073 Gottingen, Germany
[10] Krankenhaus NW Frankfurt, Frankfurt, Germany
[11] Sahlgrens Univ Hosp, Gothenburg, Sweden
[12] Haukeland Hosp, Oslo, Norway
[13] Oulu Univ Hosp, Oulu, Finland
[14] Helsinki Univ Hosp, Helsinki, Finland
[15] 4Pharma, Turku, Finland
[16] Univ Klinikum Mannheim, Mannheim, Germany
[17] Lund Univ, Lund, Sweden
[18] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase III trial 22961
    Bolla, M.
    Van Tienhoven, G.
    De Reijke, T. H. M.
    Van den Bergh, F.
    Oddens, J. O. R. G.
    Poortmans, P.
    Gez, E.
    Kil, P.
    Musat, E.
    Collette, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 279 - 279
  • [42] Final results of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first line treatment in patients with RAS wild -type metastatic colorectal cancer (mCRC)
    Geissler, M.
    Tannapfel, A.
    Reinacher-Schick, A.
    Martens, U.
    Ricke, J.
    Riera-Knorrenschield, J.
    Kanzler, S.
    Held, S.
    Heinemann, V.
    Seufferlein, T.
    Modest, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial
    Naoto Takahashi
    Mitsuro Kanda
    Takaki Yoshikawa
    Nobuhiro Takiguchi
    Kazumasa Fujitani
    Katsufumi Miyamoto
    Yuichi Ito
    Osamu Takayama
    Motohiro Imano
    Norio Mitsumori
    Junichi Sakamoto
    Satoshi Morita
    Yasuhiro Kodera
    Gastric Cancer, 2018, 21 : 1014 - 1023
  • [44] A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial
    Takahashi, Naoto
    Kanda, Mitsuro
    Yoshikawa, Takaki
    Takiguchi, Nobuhiro
    Fujitani, Kazumasa
    Miyamoto, Katsufumi
    Ito, Yuichi
    Takayama, Osamu
    Imano, Motohiro
    Mitsumori, Norio
    Sakamoto, Junichi
    Morita, Satoshi
    Kodera, Yasuhiro
    GASTRIC CANCER, 2018, 21 (06) : 1014 - 1023
  • [45] Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
    Matikas, Alexios
    Moebus, Volker
    Greil, Richard
    Andersson, Anne
    Steger, Guenther G.
    Untch, Michael
    Fornander, Tommy
    Malmstroem, Per
    Schmatloch, Sabine
    Johansson, Hemming
    Hellstroem, Mats
    Brandberg, Yvonne
    Gnant, Michael
    Loibl, Sibylle
    Foukakis, Theodoros
    Bergh, Jonas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (26)
  • [46] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Kyung-Ha Lee
    In Jun Yang
    Gi Won Ha
    Jaeim Lee
    Youn Young Park
    Suk Hwan Lee
    Jong Min Lee
    Jung Hoon Bae
    Eun Jung Park
    Hyungjin Kim
    Keun Young Kim
    Sanghyung An
    Ik Yong Kim
    Ji Yeon Kim
    BMC Cancer, 24
  • [47] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Lee, Kyung-Ha
    Yang, In Jun
    Ha, Gi Won
    Lee, Jaeim
    Park, Youn Young
    Lee, Suk Hwan
    Lee, Jong Min
    Bae, Jung Hoon
    Park, Eun Jung
    Kim, Hyungjin
    Kim, Keun Young
    An, Sanghyung
    Kim, Ik Yong
    Kim, Ji Yeon
    BMC CANCER, 2024, 24 (01)
  • [48] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
    Yamazaki, K.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Oki, E.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 77 - 84
  • [49] Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
    Lancet, Jeffrey E.
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael
    Louie, Arthur Chin
    Medeiros, Bruno C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] COST-EFFECTIVENESS ANALYSIS OF THREE YEAR VERSUS ONE YEAR IMATINIB FOR THE TREATMENT OF PATIENTS AT HIGH RISK OF DISEASE RECURRENCE FOLLOWING SURGICAL RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMOURS (GIST)
    Nagy, B.
    Gray, L.
    Ward, S. E.
    ANNALS OF ONCOLOGY, 2012, 23 : 235 - 236
12345